Friday, 16 November 2018

Strides Shasun receives USFDA approval for Cinacalcet Hydrochloride tablets

02 May 2018 | News

Cinacalcet Hydrochloride tablets is a generic version of Sensipar tablets of Amgen Inc

Drug firm Strides Shasun’s wholly-owned subsidiary Strides Pharma Global has received approval from the US health regulator for Cinacalcet Hydrochloride tablets, used for treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease on dialysis. 

Strides Pharma has received final approval for Cinacalcet Hydrochloride tablets, 30 mg (base), 60 mg (base), and 90 mg (base) from the United States Food & Drug Administration (USFDA)". 

Cinacalcet Hydrochloride tablets is a generic version of Sensipar tablets of Amgen Inc. 

Citing IQVIA data, the company said the US market for the approved product is approximately USD 1.8 billion. 

The product will be manufactured at the company's oral dosage facility at Puducherry and will be marketed by Strides Pharma Inc. in the US Market.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Click Here!




Survey Box

Will the health insurance sector receive benefits from Ayushman Bharat?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls